Global Bladder Cancer Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Bladder Cancer Market was valued at $4.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.5% CAGR, to an estimated market size of $7.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global bladder cancer market encompasses the diagnosis, treatment, and management of various forms of bladder cancer, primarily urothelial carcinoma, as well as squamous cell and adenocarcinoma. The scope includes therapeutic interventions such as immunotherapy, chemotherapy, targeted therapies, and antibody-drug conjugates (ADCs), alongside diagnostic tools like cystoscopy, biomarker testing, and surgical procedures like TURBT.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Bladder Cancer Market in the period 2025-30:
- The rapid adoption of immune checkpoint inhibitors and antibody-drug conjugates (ADCs) is significantly improving survival rates and displacing traditional chemotherapy.
- A major shift toward personalized medicine is occurring, utilizing genomic profiling and biomarker testing to tailor treatments to specific genetic mutations like FGFR3.
- Persistent supply chain shortages of BCG therapy are forcing clinicians to adopt alternative intravesical chemotherapy combinations and novel recombinant treatments.
- The integration of artificial intelligence and machine learning is enhancing diagnostic accuracy through advanced predictive models and automated imaging analysis.
- There is a growing preference for minimally invasive surgical procedures, such as robotic-assisted radical cystectomy, to reduce recovery times and hospital stays.
- The market is seeing a rise in combination therapies, particularly the pairing of immunotherapy with chemotherapy or radiation to overcome treatment resistance.
- Regulatory agencies are streamlining approval processes for innovative therapies targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Surgery & Others